| Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. | |
| | |
MedLine Citation:
|
PMID: 12496859 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
With the recent Southwest Oncology Group (SWOG) publication of their metastatic prostate cancer clinical trial results, which concluded that orchiectomy and flutamide as maximal androgen blockade (MAB) therapy vs orchiectomy alone does not significantly improve survival (NCI 0105), and the 1989 publication from the same cooperative group indicating a 24% improvement in survival for MAB therapy with leuprolide and flutamide versus leuprolide alone (NCI 0036), clinicians may well be undecided about the likelihood of clinical benefits with flutamide in combination with medical or surgical castration. To better characterize this important therapeutic decision, we assessed the survival benefit of MAB therapy with flutamide through a meta-analysis of up-to-date information from studies reported/conducted from 1989 through 1998. All peer-reviewed published randomized controlled trials comparing treatment with flutamide plus either lutenizing hormone releasing hormone (LhRH) agonists or orchiectomy as MAB treatment with LhRH or orchiectomy alone were included. The primary objective of the study was to form a combined estimate and confidence interval for the hazard ratio (as measured by the relative risk (RR) of survival in a comparison of castration vs MAB) summarizing the effect of flutamide treatment on overall survival. Directly extracted estimates of the log hazard ratio were used if available (1 study); if not, either an estimate of the RR based on a reported P-value from a log rank test (7 studies) or a discrete proportional hazards approximation based on reconstructed annual life tables for the treatment arms (1 study) were used. Nine studies with 4128 patients with advanced prostate cancer were included in these analyses. Pooled estimates demonstrated a 10% improvement in overall survival with flutamide as MAB therapy (relative risk (RR)=0.90, 95% Confidence Interval=0.79, 1.00). The currently available updated evidence from randomized trials shows a 10% benefit in overall survival with flutamide as MAB therapy in comparison to conventional castration, almost identical to the estimate reported in the recently published Southwest Oncology Group Study (NCI 0105). |
| | |
Authors:
|
C L Bennett; T D Tosteson; B Schmitt; P D Weinberg; M S Ernstoff; S D Ross |
Related Documents
:
|
7642429 - Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. 19880259 - No impairment of quality of life 18 months after high-dose intensity-modulated radiothe... 1422689 - Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combi... 6697289 - Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patient... 23179729 - Outcomes of salvage prostate cryotherapy stratified by pre-treatment psa: update from t... 1382829 - A phase ii study of recombinant human alpha-interferon in advanced hormone-refractory p... 23295799 - Palliative radiation therapy practice in patients with metastatic non-small-cell lung c... 21723689 - Survival after lung metastasectomy for colorectal cancer: importance of previous liver ... 3965079 - Medulloblastoma. period of risk reviewed. |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Prostate cancer and prostatic diseases Volume: 2 ISSN: 1476-5608 ISO Abbreviation: Prostate Cancer Prostatic Dis. Publication Date: 1999 Jan |
Date Detail:
|
Created Date: 2002-Dec-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815755 Medline TA: Prostate Cancer Prostatic Dis Country: - |
Other Details:
|
Languages: ENG Pagination: 4-8 Citation Subset: - |
Affiliation:
|
The Robert H Lurie Cancer Center, the Division of Hematology/Oncology and the Institute for Health Services and Policy Research Studies, Northwestern University and the Chicago VA Healthcare System/Lakeside Division, Chicago, Illinois. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Medical therapy for BPH: expanding our treatment paradigm?
Next Document: Genetic predisposition to prostate cancer.